[ad_1]
New York, December 3, 2021 /PRNewswire/ – According to a recent study by Persistence Market Research, Global CAR-T cell therapy market It is expected to achieve rapid growth in the next few years.The market is expected to grow from $1.2 billion 2020 to US$2.8 billion By 2031, this reflects a compound annual growth rate of approximately 5.6% over the next ten years.
Major players in the CAR T cell therapy field focus on acquisitions and cooperation with other players in the market to strengthen their position by offering a wide range of products.
For example, in December 2017, Gilead Science acquired Cell Design Labs Inc., a privately held biotherapy company that discovers and develops cell-based therapies. The acquisition benefits Gilead by acquiring a new technology platform, which will promote its research and development work in cell therapy.
In addition, more and more clinical trials in the fields of life sciences and CAR T cells will help manufacturers and researchers develop innovative cancer therapies. With a large amount of research surrounding CAR T cell therapy, it is expected that the availability of products on the market will increase in the next few years.
- For example, an experiment on anti-CD19 chimeric antigen receptor T cells for the treatment of relapsed or refractory non-Hodgkin’s lymphoma Benjamin Tomlinson Ongoing, and currently undergoing phase I clinical trials.
- Another study by Janssen Research & Development, LLC on chimeric antigen receptor T cell (CAR-T) therapy…
The full story can be found on Benzinga.com
[ad_2]
Source link
